କାନାବିଡିଓଲ

ଉଇକିପିଡ଼ିଆ‌ରୁ
Jump to navigation Jump to search
କାନାବିଡିଓଲ
Cannabidiol.svg
CBD-3D-balls.png
Clinical data
Trade namesEpidiolex, Epidyolex
SynonymsCBD, cannabidiolum, (−)-cannabidiol[୩]
AHFS/Drugs.commonograph
MedlinePlusa618051
data
Pregnancy
category
Routes of
administration
By mouth[୨]
Legal status
Legal status
Pharmacokinetic data
BioavailabilityBy mouth: 6% (fasted)[୮]
Inhaled: 31% (11–45%)[୯]
Elimination half-life18–32 hours[୧୦]
Identifiers
ECHA InfoCard100.215.986 Edit this at Wikidata
Chemical and physical data
FormulaC21H30O2
Molar mass୩୧୪.୪୭ g·mol−1
3D model (JSmol)
Melting point66 °C (151 °F)
Solubility in waterinsoluble mg/mL (20 °C)
  (verify)
<span title="International nonproprietary name (INN): <nowiki>Mr. Ibrahem/Cannabidiol</nowiki>">Mr. Ibrahem/Cannabidiol
Clinical data
Trade names Epidiolex, Epidyolex
Other names CBD, cannabidiolum, (−)-cannabidiol[୧୧]
AHFS/Drugs.com Monograph
MedlinePlus a618051
License data
  • <abbr class="country-name" title="<nowiki>European Union</nowiki>">EU EMAby INN
  • <abbr class="country-name" title="<nowiki>United States</nowiki>">US DailyMedCannabidiol
Pregnancy

category
  • <abbr class="country-name" title="<nowiki>Australia</nowiki>">AU: B2[୧୨]
Routes of

administration
By mouth[୧୨]
Drug class Cannabinoid[୧୨]
Legal status
Legal status
  • <abbr class="country-name" title="<nowiki>Australia</nowiki>">AU: S3 (Pharmacist only)
  • <abbr class="country-name" title="<nowiki>Canada</nowiki>">CA: Unscheduled
  • <abbr class="country-name" title="<nowiki>United Kingdom</nowiki>">UK: POM (Prescription only) [୧୨][୧୨]
  • <abbr class="country-name" title="<nowiki>United States</nowiki>">US: Schedule V / Rx-only[୧୨][୧୩]
  • <abbr class="country-name" title="<nowiki>European Union</nowiki>">EU: Rx-only [୧୨]
Pharmacokinetic data
Bioavailability By mouth: 6% (fasted)[୧୨]

Inhaled: 31% (11–45%)[୧୨]
Elimination half-life 18–32 hours[୧୨]
Identifiers
  • 2-[(1R,6R)-6-Isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
Chemical and physical data
Formula C21H30O2
Molar mass 314.469 g·mol−1
3D model (JSmol)
Melting point 66 °C (151 °F)
Solubility in water insoluble
  • Oc1c(c(O)cc(c1)CCCCC)[C@@H]2\C=C(/CC[C@H]2\C(=C)C)C
  • InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18+/m0/s1{PubChem}
  • Key:QHMBSVQNZZTUGM-ZWKOTPCHSA-N{PubChem}
  (verify)

କାନାବିଡିଓଲ ( ସିବିଡି ) ହେଉଛି ଏକ କାନନାବିନଏଡ୍ ଯାହା ଔଷଧ ଭାବାରେ ବାତ, ଟ୍ୟୁବରସ ସ୍କ୍ଲେରୋସିସ୍ କମ୍ପ୍ଲେକ୍ସ, ଲେନୋକ୍ସ-ଗାଷ୍ଟାଉଟ ଏବଂ ଡ୍ରାଭେଟ୍ ସିଣ୍ଡ୍ରୋମରେ ଇତ୍ୟାଦି ରୋଗମାନଙ୍କର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ । [୧୪] [୧୫] [୧୨] ଏହା କ୍ଲୋବାଜାମ ସହିତ ଏକତ୍ର ବ୍ୟବହୃତ ହୁଏ । [୧୬] ଏହା ପାଟିରେ ଦିଆଯାଏ । [୧୬] ୨୦୧୯ ସୁଦ୍ଧା ଉଦ୍‌ବେଗ, ସାଇକୋସିସ୍ କିମ୍ବା ଯନ୍ତ୍ରଣା ପାଇଁ ଏହାର ବ୍ୟବହାରକୁ ସମର୍ଥନ କରିବା ପାଇଁ ପ୍ରମାଣ ପର୍ଯ୍ୟାପ୍ତ ନୁହେଁ । [୧୭] [୧୮]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଉତ୍ତେଜନା, ତରଳ ଝାଡ଼ା, ଥକାପଣ, ଶୋଇବାରେ ଅସୁବିଧା ଏବଂ ରାସ ଅନ୍ତର୍ଭୁକ୍ତ । [୧୪] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଯକୃତ ସମସ୍ୟା ଏବଂ ଆତ୍ମହତ୍ୟା ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ । [୧୨] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର ଶିଶୁର କ୍ଷତି କରିପାରେ । [୨] ଏହାର କାର୍ଯ୍ୟଶୈଳୀ ସଂପୂର୍ଣ୍ଣ ସ୍ପଷ୍ଟ ନୁହେଁ । [୧୨] ଏହାର ଟେଟ୍ରାହାଇଡ୍ରୋକାନାବିନୋଲ (THC) ପରି ସମାନ ସାଇକୋଆକ୍ଟିଭ୍ ଗୁଣ ନାହିଁ । [୧୯]

୧୯୪୦ରେ କାନନାବିଡିଓଲ ଆବିଷ୍କୃତ ହୋଇଥିଲା। [୧୨] ଏହା ୨୦୧୮ରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏବଂ ୨୦୧୯ ରେ ୟୁରୋପରେ ଚିକିତ୍ସା ପାଇଁ ଅନୁମୋଦିତ ହୋଇଥିଲା। [୧୨] [୧୨] ଯୁକ୍ତରାଷ୍ଟରେ ୨୦୨୧ରେ ଏହାର ୧୦୦ମିଗ୍ରା/ମିଲି ଦ୍ରବଣର ୩୦୦ମିଲିର ମୂଲ୍ୟ ୪୬୦୦ ଡଲାର ଥିଲା । [୨୦] ଏହା କାନାବିସ୍ ସାଟିଭା ଗଛରି ତିଆରି ହୁଏ । [୧୯] କିଛି ଲୋକ ଏହାକୁ ସିବିଡି (CBD) ତେଲ ଆକାରରେ ବ୍ୟବହାର କରନ୍ତି ଯେଉଁଥିରେ ସାଧାରଣତ ନିମ୍ନ ସ୍ତରର ଟିଏଚସି (THC) ଥାଏ । [୧୮]

ଆଧାର[ସମ୍ପାଦନା]

  1. "Epidyolex". Therapeutic Goods Administration (TGA). 29 September 2020. Archived from the original on 30 October 2021. Retrieved 30 September 2020.
  2. ୨.୦ ୨.୧ ୨.୨ "Epidiolex- cannabidiol solution". DailyMed. 26 August 2020. Archived from the original on 25 February 2021. Retrieved 11 September 2020.
  3. "cannabidiol (CHEBI:69478)". www.ebi.ac.uk. Archived from the original on 2021-05-12. Retrieved 2021-10-30.
  4. "Epidyolex EPAR". European Medicines Agency (EMA). 24 June 2019. Archived from the original on 9 August 2021. Retrieved 11 September 2020. Text was copied from this source which is copyrighted by the European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. "Epidyolex 100 mg/ml oral solution - Summary of Product Characteristics (SmPC)". (emc). 28 August 2020. Archived from the original on 16 February 2021. Retrieved 11 September 2020.
  6. "Sativex Oromucosal Spray - Summary of Product Characteristics (SmPC)". (emc). 25 August 2020. Archived from the original on 4 February 2021. Retrieved 11 September 2020.
  7. "LeafPro CBDmed Oil FS QP 20%- cannabidiol oil". DailyMed. 9 March 2020. Archived from the original on 1 November 2021. Retrieved 11 September 2020.
  8. Perucca E, Bialer M (5 June 2020). "Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications". CNS Drugs. 34 (8): 795–800. doi:10.1007/s40263-020-00741-5. PMID 32504461. S2CID 219313952.
  9. Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G (May 2009). "Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders". Phytotherapy Research (Review). 23 (5): 597–602. doi:10.1002/ptr.2625. PMID 18844286. S2CID 21836765. Archived from the original on 2021-04-11. Retrieved 2021-10-30.
  10. Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, et al. (June 2014). "Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders". Epilepsia. 55 (6): 791–802. doi:10.1111/epi.12631. PMC 4707667. PMID 24854329.
  11. "cannabidiol (CHEBI:69478)". www.ebi.ac.uk. Archived from the original on 2021-05-12. Retrieved 2021-10-30.
  12. ୧୨.୦୦ ୧୨.୦୧ ୧୨.୦୨ ୧୨.୦୩ ୧୨.୦୪ ୧୨.୦୫ ୧୨.୦୬ ୧୨.୦୭ ୧୨.୦୮ ୧୨.୦୯ ୧୨.୧୦ ୧୨.୧୧ ୧୨.୧୨ ୧୨.୧୩ ୧୨.୧୪ ୧୨.୧୫
  13. "Epidiolex- cannabidiol solution". DailyMed. 26 August 2020. Archived from the original on 25 February 2021
  14. ୧୪.୦ ୧୪.୧ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 326. ISBN 978-0857114105.
  15. "Cannabidiol Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 27 October 2020. Retrieved 7 January 2022.
  16. ୧୬.୦ ୧୬.୧ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 326. ISBN 978-0857114105.
  17. Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, Farrell M, Degenhardt L (December 2019). "Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis". The Lancet. Psychiatry. 6 (12): 995–1010. doi:10.1016/S2215-0366(19)30401-8. PMC 6949116. PMID 31672337. {{cite journal}}: Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help)
  18. ୧୮.୦ ୧୮.୧ VanDolah HJ, Bauer BA, Mauck KF (September 2019). "Clinicians' Guide to Cannabidiol and Hemp Oils". Mayo Clinic Proceedings. 94 (9): 1840–1851. doi:10.1016/j.mayocp.2019.01.003. PMID 31447137.
  19. ୧୯.୦ ୧୯.୧ Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS (December 2012). "Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences (Review). 367 (1607): 3364–78. doi:10.1098/rstb.2011.0389. PMC 3481531. PMID 23108553.
  20. "Epidiolex Prices and Epidiolex Coupons - GoodRx". GoodRx. Archived from the original on 5 August 2021. Retrieved 7 January 2022.